|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Western blot assay was used to detect the expression of PDCD4 and related proteins in the ERK1/2 pathway in osteosarcoma cells.
|
31637737 |
2020 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The study intends to study whether H4K12ac participates in regulating the carcinogenic effect of Ras-ERK1/2 on osteosarcoma (OS).
|
30942624 |
2019 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, whether H2BK12ac joins in Ras-ERK1/2 activation-induced osteosarcoma (OS) cell behaviors remain unclear.
|
31695502 |
2019 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Honokiol induces apoptosis and autophagy via the ROS/ERK1/2 signaling pathway in human osteosarcoma cells in vitro and in vivo.
|
29410403 |
2018 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The study was designed to explore the role of ERK1/2 in WNT5A/SRC-induced osteosarcoma cells invasion and the downstream target of the SRC/ERK1/2 signalings.
|
29345412 |
2018 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, our study demonstrated that DGKZ might act as an oncogene in osteosarcoma via its possible interaction with ERK1/2 and MYC pathway.
|
30662872 |
2018 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-PD1 antibody led to a significant decrease in the number of OS lung metastases, enhanced tumor apoptosis, decreased tumor cell proliferation, and p-STAT-3/p-Erk1/2 signaling blockade in OS lung tumors.
|
29733528 |
2018 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ERK inhibition (by MEK162/U0126) or knockdown (by targeted ERK1/2 shRNAs) dramatically sensitized CZ415-induced osteosarcoma cell apoptosis.
|
29137241 |
2017 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
An antibody array indicated that Erk1/2 (Thr202/Tyr204), PARS40 (Thr246), and GSK3β (Ser9) expression are affected by CARM1, and western blotting verified that CARM1 promotes OS cell proliferation via pGSK3β/β-catenin/cyclinD1 signaling.
|
28924379 |
2017 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, we provide evidence demonstrating that UA mediates caspase-dependent and ERK1/2 MAPK-associated apoptosis in osteosarcoma MG-63 cells.
|
27171502 |
2016 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of ERK1/2 Signaling Pathway is Involved in Melatonin's Antiproliferative Effect on Human MG-63 Osteosarcoma Cells.
|
27832629 |
2016 |
|
Osteosarcoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Lastly, the expression of PLA2G16 is strongly correlated with the increased ERK1/2 phosphorylation in human osteosarcoma samples, and the combined lesions are associated with reduced overall and metastasis-free survival.
|
26933804 |
2016 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, targeting of the ADM/ADM acceptors/ERK1/2/Bcl-2 pathway may provide a potential strategy through which to induce the apoptosis of osteosarcoma cells.
|
26035796 |
2015 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Secreted clusterin (sCLU) regulates cell proliferation and chemosensitivity to cisplatin by modulating ERK1/2 signals in human osteosarcoma cells.
|
25106434 |
2014 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that ERK1 and STAT3 expression are good predictive markers for chemotherapy response and that inhibitors might be used in combination with common chemotherapeutic drugs in conventional osteosarcomas.
|
25146150 |
2014 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nutlin-3 induced the phosphorylation of EGFR, MAPK/ERK kinase (MEK)1/2 and extracellular signal-regulated kinase (ERK)1/2 in U2OS human osteosarcoma cells harboring wild-type p53.
|
23314357 |
2013 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The findings imply that Caprin-1 may have a metastasis promoting role in OS and show that through resistance to apoptosis and via the activation of Akt and ERK1/2 pathways, Caprin-1 is significantly involved in the development of OS metastasis.
|
23528710 |
2013 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma.
|
23507142 |
2013 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
An inhibitor of MEK1 activation (PD98059) that prevents downstream extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation and a specific inhibitor of p38 were also used as mitogen activated protein kinase-targeting therapy is being investigated as a treatment modality for osteosarcoma.
|
23262982 |
2013 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data reveal that RNAi-mediated downregulation of ERK1/2 expression can lead to potent antitumor activity and chemosensitizing effects in human osteosarcoma.
|
22179790 |
2012 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Taken together, these findings show that GSTP1 contributes to doxorubicin and cisplatin resistance in osteosarcoma, which may be mediated in part by the activation of extracellular signal-regulated kinase 1/2.
|
17513610 |
2007 |